

TACT²

TRIAL TO ASSESS CHELATION THERAPY



- **TACT2** follows up the positive results of TACT, an NIH-sponsored multicenter, double-blind efficacy trial (*see detailed results below*)
- **TACT2** is currently in a planning year funded by NCCIH
- We are looking for trial sites to enroll, infuse and follow patients
- **TACT2** will test the most effective drug combination (**EDTA chelation + oral vitamins**) in the population that demonstrated the greatest benefit (post-MI diabetic patients) in TACT
- Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute are leading **TACT2**

TACT Summary of Results

Post MI > 50 y old, creat < 2.0a	Endpoint	Treatment Comparison	Reduction %	P	5-yr NNT
Overall	Primary	EDTA v Placebo	18%	0.035	18
Overall	Primary	EDTA + oral MVM vs. Placebo + placebo	26%	0.016	12
Diabetes	Primary	EDTA v Placebo	41%	0.0002	6.5
Diabetes	Death	EDTA v Placebo	43%	0.011	12
Diabetes	Primary	EDTA + oral MVM vs. Placebo + placebo	51%	<0.001	5.5

MVM= multivitamins and multiminerals. NNT= number needed to treat to prevent an event. Primary endpoint = death, MI, stroke, coronary revascularization, hospitalization for angina

For more information, contact the Study Chairman, Dr. Gervasio Lamas, at gervasiolamas@gmail.com, @GLamasMD on Twitter, or (305) 674-2260.